Abdelrahman Yousef
YOU?
Author Swipe
View article: Supplementary Figure S2 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Supplementary Figure S2 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer Open
Figure S2 shows characterization of KRAS G12C and G12D tumors.
View article: Supplementary Table S3 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Supplementary Table S3 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer Open
Supplementary Table S3 shows the percentage of immune cells in mouse KRAS G12C and G12D tumors tissues.
View article: Supplementary Figure S3 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Supplementary Figure S3 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer Open
Figure S3 shows KRAS G12C inhibitor reprograms PDAC tumor microenvironment.
View article: Supplementary Table S2 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Supplementary Table S2 from KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer Open
Supplementary Table S2 shows percentage of different cell types in mouse KRAS G12C and G12D tumor tissues.
View article: Interleukin-16 Serum Levels and Gene Polymorphism in Patients with Acne Vulgaris
Interleukin-16 Serum Levels and Gene Polymorphism in Patients with Acne Vulgaris Open
View article: Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variants
Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variants Open
Background Only a subset of polymerase epsilon ( POLE ) mutations is associated with hypermutant phenotype; we hypothesized that only loss-of-proofreading (LOP) POLE mutations are associated with favorable immunotherapy response. Methods T…
View article: 1288 TME and molecular characteristics of <i>KRAS</i> <sup>Q61</sup> mutated gastrointestinal malignancies and clinical outcomes
1288 TME and molecular characteristics of <i>KRAS</i> <sup>Q61</sup> mutated gastrointestinal malignancies and clinical outcomes Open
View article: Upper gastrointestinal symptoms and Gulf War Illness in a clinical cohort of US veterans: a retrospective, cross-sectional study
Upper gastrointestinal symptoms and Gulf War Illness in a clinical cohort of US veterans: a retrospective, cross-sectional study Open
Objective Approximately 30% of the 700 000 US Gulf War Veterans (GWVs) report symptoms collectively termed Gulf War Illness (GWI), a multisymptom illness of uncertain pathophysiology. Prior studies in GWI focus on overlap with irritable bo…
View article: 17P Clinical utility of liquid biopsy in patients with metastatic non-resectable CRC
17P Clinical utility of liquid biopsy in patients with metastatic non-resectable CRC Open
View article: KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma Open
View article: Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis
Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis Open
View article: BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy Open
View article: Supplementary Table S3 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Table S3 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Table S3: 70 gene ctDNA panel
View article: Supplementary Table S2 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Table S2 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Table S2: Co-occuring circulating mutations in AA
View article: Data from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Data from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Purpose:Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adeno…
View article: Supplementary Table S1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Table S1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Table 1: Actionable mutations noted in ctDNA of AA patients
View article: Supplementary Data 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Data 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Appendiceal Adenocarcinoma Circulating Mutational Profiles
View article: Supplementary Figures 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Figures 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Figures
View article: Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma
Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma Open
These molecularly profiled, orthotopic PDX models of metastatic AA represent a unique resource for future exploration to identify novel therapies for this orphan disease.
View article: The Landscape of ctDNA in Appendiceal Adenocarcinoma
The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal aden…
View article: Single-cell RNA sequencing of appendiceal adenocarcinoma reveals a low proportion of epithelial cells and a fibroblast enriched tumor microenvironment
Single-cell RNA sequencing of appendiceal adenocarcinoma reveals a low proportion of epithelial cells and a fibroblast enriched tumor microenvironment Open
Background: Appendiceal adenocarcinoma (AA) is an understudied gastrointestinal malignancy. Treatment is guided by its proximal counterpart, colorectal cancer (CRC), despite recent studies demonstrating AA’s unique mutational landscape and…
View article: Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series Open
Objectives: Acinar cell carcinoma (ACC) accounts for about 1% of pancreatic cancers. The molecular and clinical features of ACC are less characterized than those of pancreatic ductal adenocarcinoma. Methods: We retrospectively evaluated th…
View article: Data from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
Data from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma Open
Appendiceal adenocarcinomas (AAs) are a rare and heterogeneous mix of tumors for which few preclinical models exist. The rarity of AA has made performing prospective clinical trials difficult, which has partly contributed to AA remaining a…
View article: Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma Open
Figure S1-S8
View article: Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma Open
Figure S1-S8
View article: Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single Institution Case Series
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single Institution Case Series Open
Acinar cell carcinoma (ACC) accounts for about 1% of pancreatic cancers. The molecular and clinical features of ACC are less characterized than pancreatic ductal adenocarcinoma. We retrospectively evaluated the clinical and molecular featu…
View article: Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma Open
Background The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) is poor. Secondary brain metastasis (Br-M) occurs in less than 1% of patients. Clinical characteristics and molecular alterations have not been characterize…
View article: Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma Open
Purpose:Appendiceal adenocarcinoma (AA) remains an orphan disease with limited treatment options for patients unable to undergo surgical resection. Evidence supporting the efficacy of combined VEGF and PD-1 inhibition in other tumor types …
View article: Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma Open
Supplementary Figure 1: Consort Diagram Trial consort diagram
View article: Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma Open
Supplementary Figure 1: Consort Diagram Trial consort diagram